Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients with Chest Wall Breast Cancer (PERICLES): an immune-biomarker analysis of tumor infiltrating lymphocytes (TILs) and programmed cell death ligand protein 1 (PD-L1)

被引：1
|
作者：
Valenza, Carmine
Giachetti, Pier Paolo Maria Berton
Zagami, Paola
Nicolo, Eleonora
Trapani, Dario
Boldrini, Laura
Salimbeni, Beatrice Taurelli
Ascione, Liliana
Antonarelli, Gabriele
Corti, Chiara
Esposito, Angela
Criscitiello, Carmen
Fusco, Nicola
Curigliano, Giuseppe
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-14-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-14-05
引用
收藏
页数：4
相关论文
共 50 条
  • [11] The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)
    Tomioka, Nobumoto
    Azuma, Manabu
    Ikarashi, Mayuko
    Yamamoto, Mitsugu
    Sato, Masako
    Watanabe, Ken-ichi
    Yamashiro, Katsushige
    Takahashi, Masato
    BREAST CANCER, 2018, 25 (01) : 34 - 42
  • [12] The association of programmed death-ligand 1 (PD-L1), programmed cell death (PD-1), tumor infiltrating lymphocytes(TILs) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM)
    Dede, D. Sener
    Dogan, H. Tatli
    Asan, F. B.
    Ocal, B. Gumuskaya
    Ayik, S.
    Sendur, M. A. N.
    Ulas, A.
    Bilgin, B.
    Hizal, M.
    Akinci, M. B.
    Silay, K.
    Yalcin, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [13] TUMOR INFILTRATING LYMPHOCYTES AND PROGRAMMED DEATH LIGAND 1 (PD-L1) EXPRESSION IN DIFFUSE AND ANAPLASTIC GLIOMAS
    Berghoff, A. S.
    Kiesel, B.
    Widhalm, G.
    Wilhelm, D.
    Rajky, O.
    Kurscheid, S.
    Hegi, M.
    Woehrer, A.
    Marosi, C.
    Preusser, M.
    NEURO-ONCOLOGY, 2016, 18 : 26 - 26
  • [14] Programmed death ligand 1 (PD-L1) expression and tumor infiltrating lymphocytes in diffuse and anaplastic gliomas
    Berghoff, A. S.
    Kiesel, B.
    Widhalm, G.
    Rajky, O.
    Ricken, G.
    Woehrer, A.
    Dieckmann, K.
    Zielinski, C. C.
    Marosi, C.
    Preusser, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S593 - S593
  • [15] Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
    Nunez Abad, Martin
    Calabuig-Farinas, Silvia
    Lobo de Mena, Miriam
    Torres-Martinez, Susana
    Garcia Gonzalez, Clara
    Garcia Garcia, Jose Angel
    Iranzo Gonzalez-Cruz, Vega
    Camps Herrero, Carlos
    CANCERS, 2022, 14 (02)
  • [16] Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors
    Chovanec, Michal
    Cierna, Zuzana
    Miskovska, Viera
    Machalekova, Katarina
    Svetlovska, Daniela
    Kalavska, Katarina
    Rejlekova, Katarina
    Spanik, Stanislav
    Kajo, Karol
    Babal, Pavel
    Mardiak, Jozef
    Mego, Michal
    ONCOTARGET, 2017, 8 (13) : 21794 - 21805
  • [17] Tumor infiltrating lymphocytes (TILs) and the expression of programmed death ligand 1 (PD-L1) as predictors for the response rate of preoperative systemic therapy (PST) and prognosis in triple-negative breast cancer (TNBC).
    Tomioka, Nobumoto
    Azuma, Manabu
    Hagio, Kanako
    Ikarashi, Mayuko
    Satoh, Masako
    Yamamoto, Mitsugu
    Watanabe, Ken-ichi
    Yamashiro, Katsushige
    Takahashi, Masato
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [18] Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Lorena Incorvaia
    Daniele Fanale
    Giuseppe Badalamenti
    Nadia Barraco
    Marco Bono
    Lidia Rita Corsini
    Antonio Galvano
    Valerio Gristina
    Angela Listì
    Salvatore Vieni
    Stefania Gori
    Viviana Bazan
    Antonio Russo
    Advances in Therapy, 2019, 36 : 2600 - 2617
  • [19] Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Incorvaia, Lorena
    Fanale, Daniele
    Badalamenti, Giuseppe
    Barraco, Nadia
    Bono, Marco
    Corsini, Lidia Rita
    Galvano, Antonio
    Gristina, Valerio
    Listi, Angela
    Vieni, Salvatore
    Gori, Stefania
    Bazan, Viviana
    Russo, Antonio
    ADVANCES IN THERAPY, 2019, 36 (10) : 2600 - 2617
  • [20] Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer
    Neelima Vidula
    Christina Yau
    Hope S. Rugo
    Breast Cancer Research and Treatment, 2021, 187 : 387 - 395
12345